A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
Completed · Phase 3
Conditions studied: Respiratory Syncytial Virus
In brief
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Key facts
- Study ID
- NCT07117487
- Run by
- ModernaTX, Inc.
- People needed
- 507
- Starts
- 2025-08-05
- Expected to finish
- 2026-03-27
- Last updated by the study team
- 2026-05-04
Who can join
Age: 60 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Velocity Clinical Research, Denver — Denver, Colorado, United States
- Indago Research & Health Center, Inc. — Hialeah, Florida, United States
- Velocity Clinical Research, Savannah — Savannah, Georgia, United States
- Velocity Clinical Research, Valparaiso — Valparaiso, Indiana, United States
- Velocity Clinical Research, Covington — Covington, Louisiana, United States
- Velocity Clinical Research, Rockville — Rockville, Maryland, United States
- Velocity Clinical Research, Lincoln — Lincoln, Nebraska, United States
- Velocity Clinical Research, Medford — Medford, Oregon, United States
- Velocity Clinical Research, Austin — Austin, Texas, United States
- Velocity Clinical Research, Hampton — Hampton, Virginia, United States
- Velocity Clinical Research, Spokane — Spokane, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.